Dogné, J.-M., de Leval, X., Kolh, P., Sanna, V., Rolin, S., Michaux, C., Mauer, M., David, J.-L., Masereel, B., & Pirotte, B. (January 2003). Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 68 (1), 49-54. doi:10.1016/S0952-3278(02)00236-3 |
Barthelemy, N., David, J.-L., Bosquee, L., Bury, T., Seidel, L., Albert, A., Bartsch, P., BAUGNET-MAHIEU, L., & Deneufbourg, J.-M. (March 2002). Increased TGFβ1 plasma level in patients with lung cancer: potential mechanisms. European Journal of Clinical Investigation, 32 (3), 193-198. doi:10.1046/j.1365-2362.2002.00956.x |
Gougnard, T., Charlier, C., David, J.-L., & Plomteux, G. (1999). Concentrations plasmatiques de la vitamine K1 et de l'acenocoumarol en fonction du temps de quick (I.N.R.). Acta Clinica Belgica. Supplementum, S1, 32-4. |
Bastos da Silva, M., Dessy, C., David, J.-L., & Lekeux, P. (1997). Morphological alterations of blood platelets induced by Platelet Activating Factor (PAF) and partial inhibition by Ketoprofen in calves. Veterinary Research, 28 (5 Sep-Oct), 489-502. |
Andrien, F., Lemaire, M., Beguin, Y., Bury, J., Closon, J., David, J.-L., Dejardin-Closon, M.-T., Duvivier, A., Fillet, G., & Tjean, M. (1986). Second tumors and myeloproliferative diseases after Hodgkin's disease treatment. Leukemia Research, 10, 887. |